Biocept Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Biocept Corp from these most-recent analyst ratings.
There is no price target for Biocept
There is no analyst for Biocept
There is no last upgrade for Biocept
There is no last downgrade for Biocept.
There is no next analyst rating for Biocept.
There is no next analyst rating for Biocept.
Browse analyst ratings and price targets on all stocks.